Member Info for PepeLePewle

Thanks Torquay,

Apologies, as I may have not been properly understood. I wasn't suggesting that Sath moving on was in any way a negative for Scancell. On the contrary, I think it indicates at the very least that the Scancell board wants to have in place a CFO with a wider skill-set. A CFO who has the range of skills that will enable him to lead the company to a Nasdaq listing IF that is so desired. I am impressed by the fact that Scancell appear to be prepared to take this step (I am not aware of any evidence that it wasn't at Scancell's behest, and was on the initiative of Sath himself). As far as I am concerned, it is a very strong indicator that they mean business, and it tilts the evidence towards a Nasdaq listing, or at the very least a serious intention to prepare for it.

Excellent news.

The investment thesis of a large addressable market, with no red flags, is intact.

Indeed, as the news flow strengthens the issue becomes more one of a possible inflexion point, rather than merely future prospects.

I can't help feeling the departure of a CFO is significant. There's absolutely no suggestion that Sath left under a cloud. Scancell is nothing if not stable - the board composition attests to that. No company parts ways with their CFO without very good reason, and Scancell is hardly likely to be the exception.

A listing on Nasdaq is a discrete, if challenging, event. It would need a strong board and, crucially, the right CFO. I don't see any alternative factor, such as partnering, providing adequate explanation for Sath's departure (if boards were to be "reduced" as a consequence of a partnering, then that would happen at the time of the partnering, not months before).

I think something's afoot with the departure, and I think it's linked to a possible re-listing.

Quoth - I suspect that it's now mandatory for anyone with the slightest connection with Spurs to have ACL reconstruction surgery (a private joke for any Spurs fan out there who, if they are anything like me, spends more time on the "Premier League Injury Table" site than they do watching the game).

On Verona, it is the biggest "one that got away" of my investment life...I had £10K invested at ten pence. They doubled in price, and being wet behind the ears I sat on my hands. They then went back to 10 pence. I got bored, and sold doing no more than washing my face.

Years later, after having grown disillusioned with direct investment into companies, I chanced to see the value of Verona. It was $10 billion, which would have made my original stake of £10K worth c$10 million dollars.

That episode piqued my interest in shares once again (like a moth to the flame no doubt).

The reason I ask the question is because it would be interesting if anyone happened to hold Verona from the time of its AIM- only listing all the way through to the Nasdaq spell, given the read-across to Scancell. I liked Verona because the market for COPD was (and is) huge) and because I couldn't see any red-flags...I look at Scancell, and it seems a similar situation - but with cancer treatment. I say that as someone who knows nothing re pharma, but is interested in risk assessment, and the potential of penny stocks. I have owned Scancell for a little while, and was intrigued with the departure of Sath. My overall impression of him was that he is bright, but not the man to (perhaps) lead the company into the Nasdaq.

Good morning to one and all.

This is my entre into the world of AIM chatboards (long-investor, but not particularly into the often fractious habitat of the AIM chatboard).

Two points: 1) does anyone have recollection of Verona Pharma (former AIM pharma company that switched to the Nazdaq)? and 2) does anyone have sympathy for Tottenham Hotspur - leaving aside their rather snow-flake official Supporter's Club?